

Trillium Research Chosen as Site for New Clinical Trial in Chronic Urticaria

Trillium Research selected as a site for a clinical trial studying new treatments for chronic urticaria, expanding access to innovative care in North Carolina.

CHAPEL HILL, NC, UNITED STATES, December 2, 2025 /EINPresswire.com/ -- Trillium Research, the clinical research division of Trillium Dermatology, is proud to announce its selection as a clinical trial site for a groundbreaking new study evaluating a treatment for chronic [urticaria](#), commonly known as chronic hives. This selection recognizes Trillium Research as a trusted leader in dermatologic innovation and a growing regional hub for advanced clinical research.

Urticaria affects millions of adults and children in the United States, often causing intense itching, swelling, burning, and debilitating discomfort. For many, existing therapies—including antihistamines and biologics—fail to provide sufficient relief. The new clinical trial aims to evaluate a next-generation therapeutic approach designed to improve disease control, reduce flare frequency, and improve quality of life for patients living with chronic spontaneous urticaria (CSU) or inducible urticaria.

The study will be conducted at Trillium Research's dedicated clinical research facilities in Chapel Hill, where state-of-the-art technology, highly trained research staff, and board-certified



dermatologists support a full spectrum of Phase II–IV dermatology studies.

Advancing Urticaria Care Through Research

“We are honored to be selected as a site for this important clinical trial,” said Stefan Weiss, MD, board-certified dermatologist and Director of Trillium Research. “Chronic urticaria is a condition that profoundly disrupts patients’ lives. Even with current treatments, many still struggle with daily itching, swelling, and sleep loss. New therapeutic options are urgently needed, and we are committed to being part of the solution.”

Dr. Weiss noted that chronic urticaria is frequently misunderstood as a “minor rash,” when in reality it can be a long-term inflammatory disease with unpredictable flares that interfere with work, school, and emotional well-being. While modern biologic therapies have improved outcomes for some, a considerable number of patients fail to reach adequate control—highlighting the need for continued innovation.

“This trial represents hope,” Dr. Weiss added. “Hope for patients who have tried multiple therapies without long-term success, and hope for clinicians determined to improve outcomes for those who suffer most.”

Why Trillium Research Was Chosen

Trillium Research has quickly become one of North Carolina’s rising centers for dermatologic [clinical trials](#), known for its:

- Experienced Investigators

Led by Dr. Weiss and supported by Trillium Dermatology’s full medical team, the group brings extensive experience in inflammatory skin disease research, including atopic dermatitis, psoriasis, alopecia areata, and chronic urticaria.

- Advanced Research Infrastructure

Dedicated clinical research suites, advanced photography and imaging systems, and integrated EMR and data-capture tools ensure precision, reliability, and regulatory compliance.

- Strong Patient Community

With clinics in Chapel Hill, Smithfield, and Burlington, Trillium Dermatology serves a diverse population with high rates of complex dermatologic disease—making recruitment both efficient and representative.

- Commitment to Innovation and Access

Trillium Research was founded on the belief that cutting-edge therapies should be accessible to patients across North Carolina, not just those treated at major academic centers. The selection for this trial reinforces the center's growing role in shaping the future of dermatologic care.

About the Urticaria Clinical Trial

While specific protocol details vary by sponsor and regulatory approvals, the study will evaluate an investigational therapy targeting pathways known to drive chronic urticaria symptoms. Key components of the trial include:

- Enrollment of adults with chronic spontaneous or inducible urticaria
- Assessment of itch severity, hive reduction, and flare frequency
- Evaluations of safety, quality of life, and long-term disease control
- Use of validated urticaria scoring tools and participant-reported outcomes

Participants will receive close dermatologic supervision throughout the study, including regular visits, lab assessments, and advanced monitoring. Qualified participants may receive study-related care and medication at no cost and may be compensated for time and travel.

The Patient Impact: Addressing an Urgent Need

Urticaria is often unpredictable—symptoms can appear daily, come in waves, or recur long after patients think the condition has resolved. Many individuals endure:

- Sleepless nights from itching and swelling
- Anxiety about flare unpredictability
- Difficulty concentrating at work or school
- Physical discomfort that impacts daily functioning

For patients who have failed antihistamines and existing biologics, new therapies could significantly reduce the burden of disease.

"This study is not just another data point—it's a chance to directly improve the lives of people who are still suffering," said Dr. Weiss. "We see these patients every week. They deserve better options."

Strengthening North Carolina's Role in Dermatologic Innovation

With the addition of this urticaria study, Trillium Research continues to expand its portfolio of trials spanning inflammatory skin disease, pigmentary disorders, alopecia, acne, aging skin, and rare conditions.

The center's growth reflects a larger mission: bringing world-class dermatologic research to communities across North Carolina, including Burlington, Chapel Hill, Cary, Smithfield, and surrounding regions such as Raleigh and Durham

"North Carolina is home to incredible medical expertise, and we are proud to contribute to the region's leadership in clinical research," said Dr. Weiss. "Our goal is to make sure patients don't have to travel far—or wait years—to access breakthrough therapies."

Enrollment Now Open

Trillium Research is currently evaluating and enrolling participants for the urticaria trial. Adults who have experienced chronic hives for six weeks or longer and have not achieved adequate relief with standard therapies may qualify.

Trillium Research's selection as a clinical trial site for this innovative urticaria study underscores its growing reputation as a center of excellence in dermatologic research. Through continued investment in clinical innovation and patient access, Trillium Research remains dedicated to advancing the science of skin disease and improving the lives of patients across North Carolina.

About Trillium Research

Trillium Research is the clinical research arm of Trillium Dermatology, a leading dermatology practice serving communities across central North Carolina. Focused on advancing treatments for medical dermatology conditions, Trillium Research conducts Phase II–IV clinical trials in partnership with major pharmaceutical sponsors. Led by Stefan Weiss, MD, the center is committed to delivering high-quality research, ethical study conduct, and exceptional patient care.

Stefan C Weiss MD

Trillium Clinic

+1 919-710-8100

info@trilliumclinic.com

Visit us on social media:

[Instagram](#)

[Facebook](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/870310081>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.